Bio-Rad Laboratories Class B
BIO.B
5 hedge funds and large institutions have $520K invested in Bio-Rad Laboratories Class B in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
0% more capital invested
Capital invested by funds: $518K → $520K (+$2.04K)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more ownership
Funds ownership: 0.04% → 0.04% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$473 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CL
1
CSS LLC
Chicago,
Illinois
| $269K | – | – | – |
|
2
Morgan Stanley
New York
| $170K | – | – | – |
|
3
Wells Fargo
San Francisco,
California
| $41.2K | – | – | – |
|
|
WT
4
Whittier Trust
South Pasadena,
California
| $40K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $716 | +$473 | +2 | +200% |
|
BIO.B Hedge Fund Activity: Q2 2025 in Review
5 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class B (BIO.B) for Q2 2025, worth a combined $520K — up 0.39% from $518K a quarter earlier.
Fund positioning in BIO.B was balanced in Q2 2025: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $473.
- 5 institutional investors held Bio-Rad Laboratories Class B (BIO.B) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $520K of Bio-Rad Laboratories Class B stock for Q2 2025, up 0.39% quarter-over-quarter.
- 0 funds opened new Bio-Rad Laboratories Class B positions in Q2 2025 and 0 closed out.
- The largest Bio-Rad Laboratories Class B buyer in Q2 2025 was UBS Group, an estimated $473 added.
Based on aggregated 13F filings for Q2 2025.